Cited 12 times in
Effect of diquafosol three per cent ophthalmic solution on tear film and corneal aberrations after cataract surgery
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김응권 | - |
dc.contributor.author | 김태임 | - |
dc.contributor.author | 서경률 | - |
dc.date.accessioned | 2018-07-20T08:43:04Z | - |
dc.date.available | 2018-07-20T08:43:04Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0816-4622 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/161373 | - |
dc.description.abstract | BACKGROUND: The aim was to evaluate the effect of diquafosol on tear film parameters and corneal aberrations after cataract surgery. METHODS: This retrospective, comparative, observational case series included patients who underwent cataract surgery with or without peri-operative use of diquafosol three per cent ophthalmic solution. Patients in group I (31 eyes) were treated with diquafosol three per cent ophthalmic solution six times a day from one week before surgery to three months after surgery. Patients in group II (33 eyes) underwent cataract surgery without being administered diquafosol. Tear film break-up time (BUT), the ocular surface disease index (OSDI), the Oxford Scheme score, Schirmer's test I and corneal aberrations were determined before and at one and three months post-surgery. RESULTS: In group I, the BUT, OSDI and Oxford Scheme score showed significant improvement at one and three months post-surgery (p = 0.002 for BUT at one month and three months, p = 0.023 and p = 0.049 for OSDI at one month and three months and p = 0.001 and p = 0.026 for Oxford Scheme at one month and three months), compared to baseline. In group II, the BUT, OSDI and Oxford Scheme score did not show any significant improvement during the follow-up period. In both groups, Schirmer's test I significantly decreased at three months post-surgery (p = 0.011 for group I and p = 0.034 for group II), compared to baseline. There were significant differences in the BUT and OSDI between the groups at three months post-surgery (p = 0.037 for BUT and p = 0.011 for OSDI). Regarding the corneal aberration, there were no significant differences between the groups at three months post-surgery. CONCLUSION: Peri-operative application of diquafosol three per cent ophthalmic solution may prevent dry eye-related ocular surface changes accompanied by improvement of ocular symptom. No definite changes in corneal aberrations were noted. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | Australia | - |
dc.publisher | 1444-0938 | - |
dc.relation.isPartOf | CLINICAL AND EXPERIMENTAL OPTOMETRY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aberrometry | - |
dc.subject.MESH | Administration, Ophthalmic | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Corneal Wavefront Aberration/physiopathology* | - |
dc.subject.MESH | Dry Eye Syndromes/physiopathology | - |
dc.subject.MESH | Dry Eye Syndromes/prevention & control* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lens Implantation, Intraocular* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Ophthalmic Solutions | - |
dc.subject.MESH | Perioperative Care | - |
dc.subject.MESH | Phacoemulsification* | - |
dc.subject.MESH | Polyphosphates/administration & dosage* | - |
dc.subject.MESH | Purinergic P2Y Receptor Agonists/administration & dosage* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Tears/physiology* | - |
dc.subject.MESH | Uracil Nucleotides/administration & dosage* | - |
dc.title | Effect of diquafosol three per cent ophthalmic solution on tear film and corneal aberrations after cataract surgery | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Ophthalmology | - |
dc.contributor.googleauthor | Hun Lee | - |
dc.contributor.googleauthor | Sang Myung Kim | - |
dc.contributor.googleauthor | Seonghee Choi | - |
dc.contributor.googleauthor | Kyoung Yul Seo | - |
dc.contributor.googleauthor | Eung Kweon Kim | - |
dc.contributor.googleauthor | Tae‐im Kim | - |
dc.identifier.doi | 10.1111/cxo.12521 | - |
dc.contributor.localId | A00831 | - |
dc.contributor.localId | A01080 | - |
dc.contributor.localId | A01870 | - |
dc.relation.journalcode | J03331 | - |
dc.identifier.eissn | 1444-0938 | - |
dc.identifier.pmid | 28222481 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/abs/10.1111/cxo.12521 | - |
dc.subject.keyword | OSDI | - |
dc.subject.keyword | cataract surgery | - |
dc.subject.keyword | corneal aberrations | - |
dc.subject.keyword | diquafosol | - |
dc.subject.keyword | tear film | - |
dc.contributor.alternativeName | Kim, Eung Kweon | - |
dc.contributor.alternativeName | Kim, Tae Im | - |
dc.contributor.alternativeName | Seo, Kyuong Yul | - |
dc.contributor.affiliatedAuthor | Kim, Eung Kweon | - |
dc.contributor.affiliatedAuthor | Kim, Tae Im | - |
dc.contributor.affiliatedAuthor | Seo, Kyuong Yul | - |
dc.citation.volume | 100 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 590 | - |
dc.citation.endPage | 594 | - |
dc.identifier.bibliographicCitation | CLINICAL AND EXPERIMENTAL OPTOMETRY, Vol.100(6) : 590-594, 2017 | - |
dc.identifier.rimsid | 61291 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.